Effect of 80 mg/day Simvastatin Therapy on Cardiovascular Outcomes in Adults With Versus Without Metabolic Syndrome

American Journal of Cardiology

Volumn 97, Issue 10, 2006, Pages 1487-1489

  Kamalesh, Masoor ^a   Rao, Roopa ^a   Sawada, Stephen ^a   Friend, Amy ^a   Schellhase, Ellen ^a   Evans, Tamara ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; STROKE;

ADULT; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIANA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33646173076     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.11.083     Document Type: Article

References (5)

1. Hognestad A., Aukrust P., Wergeland R, Stokke O., Gullestad L., Semb A.G., Holm T., Andreassen A.K., and Kjekshus J.K. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 27 (2004) 199-203
2. Packard C.J., and Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb 11 (2004) 6-14
3. Maki K.C., Galant R., and Davidson M.H. Non-high-density cholesterol. the forgotten therapeutic target. Am J Cardiol 96 (2005) 59-64
4. Eckel R., Grundy S.M., and Zimmet P.A. The metabolic syndrome. Lancet 365 (2005) 1415-1428
5. Pyorala K., Ballantyne C.M., Gumbiner B., Lee M.W., Shah A., Davies M.J., Mitchel Y.B., Pedersen T.R., Kjekshus J., and Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome. subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27 (2004) 1735-1740